Literature DB >> 30948987

Salvage of severe primary graft dysfunction following heart transplantation using extracorporeal life support.

Katalin Martits-Chalangari1, Omar Hernandez2, Aayla K Jamil1, Huanying Qin1, Joost Felius1, Samuel Jacob, Brian Lima1,3, Aldo Rafael1,3, Gonzalo V Gonzalez-Stawinski1,3, Melody J Sherwood1,4, Shelley A Hall1,4.   

Abstract

Primary graft dysfunction (PGD) is the leading cause of early mortality after heart transplantation. Typically, mechanical circulatory support is necessary to provide hemodynamic support and to enable graft recovery. However, both the reported incidence of PGD and the reported salvage rates with extracorporeal membrane oxygenation (ECMO) vary widely. This may partly be due to variations in the definition of PGD and its levels of severity. We analyzed a prospectively maintained database of 255 transplant recipients at our institution to determine the effectiveness of ECMO support in those who develop severe PGD as defined by the International Society for Heart and Lung Transplantation consensus guidelines. Nineteen (7.5%) patients (aged 32-69 years) developed severe PGD and were treated with veno-arterial (VA) ECMO, which was initiated in the operating room at the time of transplant in most patients. The majority received VA ECMO through femoral cannulation. Two patients required veno-venous ECMO for respiratory support after VA ECMO separation. The 30-day in-hospital survival rate following transplantation was 63% (n = 12). In conclusion, ECMO proved to be a viable option for early hemodynamic support in patients with severe PGD and has become our preferred modality for mechanical circulatory support in these patients.

Entities:  

Keywords:  Cardiac transplant; extracorporeal membrane oxygenation; mortality; severe primary graft dysfunction

Year:  2018        PMID: 30948987      PMCID: PMC6413990          DOI: 10.1080/08998280.2018.1498724

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  19 in total

1.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2011-12-15       Impact factor: 29.690

2.  Extracorporeal membrane oxygenation in primary graft failure after heart transplantation.

Authors:  Silvana F Marasco; Matthew Vale; Vince Pellegrino; Arthur Preovolos; Angeline Leet; Ashley Kras; Elliot Schulberg; Peter Bergin; Donald S Esmore
Journal:  Ann Thorac Surg       Date:  2010-11       Impact factor: 4.330

3.  The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report--2010.

Authors:  Josef Stehlik; Leah B Edwards; Anna Y Kucheryavaya; Paul Aurora; Jason D Christie; Richard Kirk; Fabienne Dobbels; Axel O Rahmel; Marshall I Hertz
Journal:  J Heart Lung Transplant       Date:  2010-10       Impact factor: 10.247

4.  Application of the International Society for Heart and Lung Transplantation (ISHLT) criteria for primary graft dysfunction after cardiac transplantation: outcomes from a high-volume centre†.

Authors:  John J Squiers; Giovanna Saracino; Themistokles Chamogeorgakis; Juan C MacHannaford; Aldo E Rafael; Gonzalo V Gonzalez-Stawinski; Shelley A Hall; J Michael DiMaio; Brian Lima
Journal:  Eur J Cardiothorac Surg       Date:  2017-02-01       Impact factor: 4.191

5.  Factors associated with primary graft failure after heart transplantation.

Authors:  Mark J Russo; Alexander Iribarne; Kimberly N Hong; Basel Ramlawi; Jonathan M Chen; Hiroo Takayama; Donna M Mancini; Yoshifumi Naka
Journal:  Transplantation       Date:  2010-08-27       Impact factor: 4.939

Review 6.  Contemporary extracorporeal membrane oxygenation therapy in adults: Fundamental principles and systematic review of the evidence.

Authors:  John J Squiers; Brian Lima; J Michael DiMaio
Journal:  J Thorac Cardiovasc Surg       Date:  2016-03-12       Impact factor: 5.209

7.  Incidence, etiology, and outcome of primary graft dysfunction in adult heart transplant recipients: a single-center experience in Japan.

Authors:  Osamu Seguchi; Tomoyuki Fujita; Yoshihiro Murata; Haruki Sunami; Takuma Sato; Takuya Watanabe; Seiko Nakajima; Kensuke Kuroda; Eriko Hisamatsu; Takamasa Sato; Masanobu Yanase; Hiroki Hata; Kyoichi Wada; Hatsue Ishibashi-Ueda; Junjiro Kobayashi; Takeshi Nakatani
Journal:  Heart Vessels       Date:  2015-02-15       Impact factor: 2.037

8.  Marginal cardiac allografts do not have increased primary graft dysfunction in alternate list transplantation.

Authors:  Brian Lima; Keshava Rajagopal; Rebecca P Petersen; Ashish S Shah; Beth Soule; G Michael Felker; Joseph G Rogers; Andrew J Lodge; Carmelo A Milano
Journal:  Circulation       Date:  2006-07-04       Impact factor: 29.690

9.  Predictive risk factors for primary graft failure requiring temporary extra-corporeal membrane oxygenation support after cardiac transplantation in adults.

Authors:  Cosimo D'Alessandro; Jean-Louis Golmard; Eleodoro Barreda; Mojgan Laali; Ralouka Makris; Charles-Edouard Luyt; Pascal Leprince; Alain Pavie
Journal:  Eur J Cardiothorac Surg       Date:  2011-03-16       Impact factor: 4.191

10.  Clinical Factors Implicated in Primary Graft Dysfunction After Heart Transplantation: A Single-center Experience.

Authors:  R A Quintana-Quezada; I Rajapreyar; A Postalian-Yrausquin; Y C Yeh; S Choi; B Akkanti; A Sieg; P Weeks; M Patel; J Patel; S Nathan; B Kar; P Loyalka; I Gregoric
Journal:  Transplant Proc       Date:  2016 Jul-Aug       Impact factor: 1.066

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.